Stocks · Healthcare · Biotechnology
CG Oncology Inc. CGON
$67.38 -1.42% Close, Oct 2, 2026 · NASDAQ · Market cap $5.94B
Strong growth
Next earnings report: Nov 13, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $6.2M, up 1030.3% from a year earlier, accelerating from 666.0% a quarter earlier.
- Operating margin widened to -4056.2% from -28546.1% a year earlier.
- The diluted share count rose 15.7% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 3%
- Revenue growth, 3-year CAGRTop 4%
- Revenue growth accelerationTop 2%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 47%
- Gross marginBottom 6%
- Operating marginBottom 7%
- Accruals (lower is better)Bottom 37%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 41%
- Free-cash-flow yieldTop 46%
- EBITDA / enterprise valueTop 48%
- Sales / enterprise valueBottom 3%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 20%
- 6-month returnBottom 43%
- 1-year return vs S&P 500Top 21%
- Distance from 52-week highTop 25%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 28%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 34%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 33%
- Maximum drawdown, 3 yearsTop 46%
- Beta vs S&P 500 (lower is better)Bottom 21%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 666.0% | 1030.3% | ↑ |
| Gross margin | -18996.2% | -82.7% | ↑ |
| Operating margin | -28546.1% | -4056.2% | ↑ |
| FCF margin | -17069.9% | -2879.6% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 1030.3% | 666.0% | ↑ | Top 3% |
| Gross margin | -82.7% | -18996.2% | ↑ | Bottom 6% |
| Operating margin | -4056.2% | -28546.1% | ↑ | Bottom 7% |
| Net margin | -3602.7% | -23245.2% | ↑ | — |
| Free-cash-flow margin | -2879.6% | -17069.9% | ↑ | — |
| Return on invested capital | -24.3% | — | Bottom 47% | |
| Revenue growth, 3-year CAGR | 176.6% | — | Top 4% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 567.2%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -1056.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -2.55%
- Shareholder yield
- -2.55%
- Share count change, 1 year
- +15.7%
- Share count change, 3-year CAGR
- +9.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -10.9%
- Average 2-day reaction, last 8
- +2.6%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $86.50
- Target vs current price
- +28.4%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -35.5% | +3.4% | +6.3% | +3.0% | — |
| May 8, 2026 | -22.4% | +0.6% | +0.5% | -22.3% | +3.2% |
| Feb 27, 2026 | +16.4% | +4.8% | +7.6% | +18.8% | +14.5% |
| Nov 14, 2025 | -2.0% | +8.6% | +7.8% | +8.4% | +41.8% |
| Aug 8, 2025 | -10.2% | +2.1% | +6.6% | +35.8% | +77.7% |
| May 13, 2025 | -15.4% | -3.9% | -1.2% | +9.2% | -3.2% |
| Mar 28, 2025 | -17.1% | -1.9% | -30.4% | -17.0% | -4.2% |
| Aug 8, 2024 | +33.3% | +7.0% | +7.0% | +20.9% | +14.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.90 | -$0.66 | -35.5% | $1.2M |
| May 8, 2026 | -$0.71 | -$0.58 | -22.4% | $1.1M |
| Feb 27, 2026 | -$0.51 | -$0.61 | +16.4% | $2.3M |
| Nov 14, 2025 | -$0.57 | -$0.56 | -2.0% | $1.7M |
| Aug 8, 2025 | -$0.54 | -$0.49 | -10.2% | — |
| May 13, 2025 | -$0.45 | -$0.39 | -15.4% | $52,000 |
| Mar 28, 2025 | -$0.48 | -$0.41 | -17.1% | $456,000 |
| Aug 8, 2024 | -$0.28 | -$0.42 | +33.3% | $111,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 952.52× | — | — | Bottom 3% |
| Free-cash-flow yield | -3.02% | — | — | Top 46% |
| Earnings yield | -4.01% | — | — | Top 41% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 274
- 50-day average slope (20 days)
- +0.5%
- 200-day average slope (20 days)
- +4.9%
- Distance from 50-day average
- -8.9%
- Distance from 200-day average
- +5.4%
- RSI (14)
- 38.6
- Relative volume
- 1.54×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 46.5%
- Volatility vs own 5-year history
- 14th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.77
- Correlation with S&P 500
- 0.44
- Current drawdown from 1-year high
- -16.5%
- Maximum drawdown, 3 years
- -67.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 16, 2024 | Apr 8, 2025 | -67.5% | 285 days | 190 days (Jan 9, 2026) |
| May 13, 2026 | Jun 5, 2026 | -27.4% | 16 days | 23 days (Jul 10, 2026) |
| Aug 19, 2026 | Sep 25, 2026 | -16.8% | 26 days | Not yet recovered |
| Jan 21, 2026 | Feb 5, 2026 | -13.9% | 11 days | 10 days (Feb 20, 2026) |
| Apr 17, 2026 | Apr 29, 2026 | -11.8% | 8 days | 10 days (May 13, 2026) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $5.94B
- EPS, diluted (TTM)
- -$2.70
- Revenue (TTM)
- $6.2M
- 52-week range
- $35.80 – $80.97
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $10.4M | $191,000 | $204,000 | $1.1M | $4.0M |
| Gross profit | $10.3M | $176,000 | -$45.5M | -$81.0M | -$607,000 |
| Operating income | -$12.6M | -$35.2M | -$55.4M | -$114.7M | -$190.8M |
| Net income | -$12.8M | -$35.4M | -$48.6M | -$88.0M | -$161.0M |
| EPS (diluted) | -$0.28 | -$0.66 | -$1.02 | -$1.41 | -$2.08 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $43,000 | $456,000 | $52,000 | $0 | $1.7M | $2.3M | $1.1M | $1.2M |
| Net income | -$20.4M | -$31.8M | -$34.5M | -$41.4M | -$43.8M | -$41.3M | -$60.2M | -$79.1M |
| EPS (diluted) | -$0.30 | -$0.49 | -$0.45 | -$0.54 | -$0.57 | -$0.52 | -$0.71 | -$0.90 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$13.7M | -$29.8M | -$45.7M | -$78.7M | -$132.3M |
| Capital expenditure | -$97,000 | -$14,000 | $0 | -$234,000 | -$134,000 |
| Free cash flow | -$13.8M | -$29.8M | -$45.7M | -$78.9M | -$132.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $245,000 | $166,000 | $2.1M | $629.5M | $153.6M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $1.03B
- Total assets
- $1.09B
- Total liabilities
- $56.5M
- Total debt
- $8.8M
- Net debt
- -$10.8M
- Shareholders’ equity
- $1.03B
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 11,254,500
- Days to cover
- 17.01
- Change vs previous report
- -1.2%
FINRA short interest, settlement date Sep 15, 2026.